WallStSmart

Medline Inc. Class A Common Stock (MDLN)vsWelltower Inc (WELL)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medline Inc. Class A Common Stock generates 162% more annual revenue ($28.43B vs $10.84B). WELL leads profitability with a 8.6% profit margin vs 4.1%. MDLN trades at a lower P/E of 29.9x. MDLN earns a higher WallStSmart Score of 52/100 (C-).

MDLN

Buy

52

out of 100

Grade: C-

Growth: 7.3Profit: 5.0Value: 8.3Quality: 7.8
Piotroski: 4/9

WELL

Hold

39

out of 100

Grade: F

Growth: 7.3Profit: 5.5Value: 2.0Quality: 7.5
Piotroski: 4/9Altman Z: 1.20
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MDLNUndervalued (+32.7%)

Margin of Safety

+32.7%

Fair Value

$66.92

Current Price

$42.03

$24.89 discount

UndervaluedFair: $66.92Overvalued
WELLSignificantly Overvalued (-2067.7%)

Margin of Safety

-2067.7%

Fair Value

$9.59

Current Price

$196.61

$187.02 premium

UndervaluedFair: $9.59Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MDLN1 strengths · Avg: 10.0/10
EPS GrowthGrowth
1255.0%10/10

Earnings expanding 1255.0% YoY

WELL2 strengths · Avg: 9.5/10
Revenue GrowthGrowth
41.3%10/10

Revenue surging 41.3% year-over-year

Market CapQuality
$136.72B9/10

Large-cap with strong market position

Areas to Watch

MDLN4 concerns · Avg: 3.0/10
P/E RatioValuation
29.9x4/10

Moderate valuation

Return on EquityProfitability
6.5%3/10

ROE of 6.5% — below average capital efficiency

Profit MarginProfitability
4.1%3/10

4.1% margin — thin

Free Cash FlowQuality
$-113.00M2/10

Negative free cash flow — burning cash

WELL4 concerns · Avg: 2.3/10
Return on EquityProfitability
2.5%3/10

ROE of 2.5% — below average capital efficiency

PEG RatioValuation
3.622/10

Expensive relative to growth rate

P/E RatioValuation
139.0x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-26.3%2/10

Earnings declined 26.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : MDLN

The strongest argument for MDLN centers on EPS Growth. Revenue growth of 14.8% demonstrates continued momentum.

Bull Case : WELL

The strongest argument for WELL centers on Revenue Growth, Market Cap. Revenue growth of 41.3% demonstrates continued momentum.

Bear Case : MDLN

The primary concerns for MDLN are P/E Ratio, Return on Equity, Profit Margin. Thin 4.1% margins leave little buffer for downturns.

Bear Case : WELL

The primary concerns for WELL are Return on Equity, PEG Ratio, P/E Ratio. A P/E of 139.0x leaves little room for execution misses.

Key Dynamics to Monitor

MDLN profiles as a value stock while WELL is a hypergrowth play — different risk/reward profiles.

WELL is growing revenue faster at 41.3% — sustainability is the question.

WELL generates stronger free cash flow (647M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MDLN scores higher overall (52/100 vs 39/100) and 14.8% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Medline Inc. Class A Common Stock

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.

Visit Website →

Welltower Inc

REAL ESTATE · REIT - HEALTHCARE FACILITIES · USA

Welltower Inc. is a real estate investment trust that invests in healthcare infrastructure.

Visit Website →

Want to dig deeper into these stocks?